Qol Holdings (3034) investor relations material

Executive summary

• Consolidated net sales rose 3.0% year-over-year to ¥73,912 million for Q1 FY2026, with significant profit growth across all segments.

• EBITDA increased 47.0% year-over-year to ¥8,757 million, and profit attributable to owners of parent surged 61.7% to ¥3,002 million.

• Growth was driven by new product launches, cost reductions in pharmaceutical manufacturing, higher technical fee unit prices in pharmacy, and increased demand in BPO contracting.

• The company announced a medium-term management plan in May 2026, focusing on growth in Pharmacy, BPO Contracting, and Pharmaceutical Manufacturing segments.

• Selected again for ESG investment indices by FTSE Russell, highlighting ongoing ESG initiatives.

Financial highlights

• Net sales: ¥73,912 million (+3.0% YoY); EBITDA: ¥8,757 million (+47.0% YoY); Operating profit: ¥6,183 million (+72.1% YoY); Ordinary profit: ¥6,159 million (+69.5% YoY); Profit attributable to owners: ¥3,002 million (+61.7% YoY).

• Gross profit for Q1 FY2026 was ¥13,025 million, up from ¥10,386 million in Q1 FY2025.

• Basic earnings per share rose to ¥79.90 from ¥49.43 year-over-year.

• Comprehensive income for Q1 FY2026 was ¥3,710 million, up 67.6% year-over-year.

• Gross profit margin improved as cost of sales declined 0.7% despite higher sales.

Outlook and guidance

• FY3/2027 full-year net sales forecast at ¥315,000 million; 1Q progress at 23.5%.

• Operating profit forecast at ¥16,500 million, with 1Q progress at 37.5%.

• Profit attributable to owners forecast at ¥7,800 million; 1Q progress at 38.5%.

• Annual dividend forecast raised to ¥54 per share (+¥4 YoY), marking four consecutive years of increases.

• No changes to previously announced financial forecasts.